Previous Close | 0.8 |
1-Year Change | -85.71% |
6-Months Change | -82.34% |
3-Months Change | 0% |
Moving Avg (50d) | 0.7004 |
Moving Avg (200d) | 2.9122 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 10.5M |
Beta (3-Years) | 0.8 |
Revenue Growth (ttm) | -5.38% |
Net Profit Margin (ttm) | 4.64% |
Return On Assets (ttm) | 2.95% |
EPS (ttm) | 0.91 |
PE Ratio (ttm) | 0.88 |
Dividend Yield | % |
Asset Description: | Eagle Pharmaceuticals, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-22 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
0.784 | 0.76 | 0.744 | 0.72 | 0.68 | 0.64 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.